hydroxypropyl-beta-cyclodextrin
Small moleculeexperimental
Clinical trial activity
17 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
10
Phase 3
3
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00914745)
Timeline
Indications
Mechanism of action
- CholesterolSEQUESTERING AGENT
Cholesterol sequestering agent
Chemistry & pharmacology
Loading structure…
SMILES
CC(O)COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]8COCC(C)O)O[C@@H]7COCC(C)O)O[C@@H]6COCC(C)O)O[C@@H]5COCC(C)O)O[C@@H]4COCC(C)O)O[C@@H]3COCC(C)O- Mol. weight
- 1541.55 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL577294 ↗
Also known as
- 2 hydroxypropyl-beta-cyclodextrin
- 2-hydroxypropyl-beta-cyclodextrin
- (2-hydroxypropyl)-gamma-cyclodextrin
- beta-hydroxypropylcyclodextrin
- hpbetacd
- hp-beta-cd
- hydroxypropyl-beta-cyclodextrin
- hydroxypropyl-beta-cyclodextrin
- hydroxypropyl-beta-cyclodextrin
- vts270
- vts-270
- vts-270
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06679322 | Phase 2 | Oct 31, 2024 | Capital Medical University |
| NCT05607615 | Phase 2 | Sep 23, 2022 | Cyclo Therapeutics, Inc. |
| NCT04860960 | Phase 3 | Jul 20, 2021 | Cyclo Therapeutics, Inc. |
| NCT04627831 | Phase 2 | Dec 31, 2020 | Ligand Pharmaceuticals |
| NCT03879655 | Phase 2/Phase 3 (Phase 3) | Aug 19, 2019 | Vtesse Inc. |
| NCT03887533 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2019 | National Institutes of Health (NIH) |
| NCT03869983 | N/A | Apr 12, 2019 | CyDex Pharmaceuticals, Ligand Pharmaceuticals, Syneos Health |
| NCT03893071 | Phase 1 | Mar 31, 2019 | Cyclotherapeutics, University of California, San Francisco |
| NCT03687476 | Phase 2 | Oct 30, 2018 | Vtesse Inc. |
| NCT03471143 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | National Institutes of Health (NIH), Washington University in St. Louis |
| NCT02939547 | Phase 1 | Apr 28, 2017 | Cyclotherapeutics |
| NCT02912793 | Phase 1/Phase 2 (Phase 2) | Mar 20, 2017 | Cyclotherapeutics, Salford Royal Foundation NHS Trust |
| NCT02534844 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2015 | Vtesse Inc. |
| NCT02418676 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Government of Brazil, State University of Maringá |
| NCT01747135 | Phase 1 | Jan 1, 2013 | National Institutes of Health (NIH), Vtesse Inc. |
| NCT00914745 | Phase 2 | Apr 1, 2009 | Devirex AG, University of Zurich |
| NCT03643562 | N/A | — | Vtesse Inc. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vtesse Inc. | For profit | 5 | 5 | 4 | 2013 |
| Cyclotherapeutics | For profit | 3 | 3 | 2 | 2017 |
| National Institutes of Health (NIH) | Government | 3 | 1 | 2 | 2013 |
| Cyclo Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Ligand Pharmaceuticals | For profit | 2 | 1 | 2 | 2019 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Government | 1 | 0 | 1 | 2013 |
| CyDex Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
| Devirex AG | For profit | 1 | 0 | 1 | 2009 |
| Government of Brazil | Government | 1 | 0 | 1 | 2013 |
| Salford Royal Foundation NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2017 |
| State University of Maringá | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Syneos Health | For profit | 1 | 0 | 1 | 2019 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Zurich | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2018 |
16 organizations
Page 1 / 1